Yuka Kubota1, Shingo Hatakeyama2, Tohru Yoneyama3, Mihoko Sutoh Yoneyama4, Itsuto Hamano1, Sakae Konishi1, Teppei Okamoto1, Hayato Yamamoto1, Takahiro Yoneyama5, Yasuhiro Hashimoto1, Chikara Ohyama1,6,5. 1. Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. 2. Department of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 036-8562, Japan. shingoh@hirosaki-u.ac.jp. 3. Department of Glycotechnology, Center for Advanced Medical Research, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. 4. Department of Cancer Immunology and Cell Biology, Oyokyo Kidney Research Institute, Hirosaki, Japan. 5. Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. 6. Department of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 036-8562, Japan.
Abstract
PURPOSE: To investigate the prognostic significance of total cell-free DNA (cfDNA) level and androgen receptor amplification (AR-amp) in patients with castration-resistant prostate cancer (CRPC). METHODS: We retrospectively compared the total cfDNA level and AR-amp in 42 individuals without prostate cancer, 57 patients with localized prostate cancer without androgen-deprivation therapy (ADT), 97 patients with castration-sensitive prostate cancer (CSPC) with ADT, and 97 patients with CRPC. The association of these cfDNA biomarkers on disease status and overall survival was evaluated using Kaplan-Meier analysis and multivariable Cox regression analysis. Finally, a simple risk model was developed including total cfDNA and AR-amp to predict poor prognosis. RESULTS: The median total cfDNA level and AR-amp in patients with CRPC was 387 pg/μL and 1.07 copies, respectively. The total cfDNA levels and AR-amp were significantly higher in the patients with CRPC than in individuals without prostate cancer, patients with localized prostate cancer without ADT, and patients with CSPC with ADT. Total cfDNA-high (> 600 pg/μL) and AR-amp-high (> 1.26 copies) were significantly associated with poor overall survival. Multivariable Cox regression analysis showed cfDNA-high and AR-amp-high were significantly associated with poor overall survival in patients with CRPC. We developed a risk model using cfDNA-high (score 1) and AR-amp-high (score 1). The risk score 1-2 was significantly associated with worse overall survival than score 0. CONCLUSION: Total cfDNA level and AR-amp are potential biomarkers for poor prognosis in patients with CRPC.
PURPOSE: To investigate the prognostic significance of total cell-free DNA (cfDNA) level and androgen receptor amplification (AR-amp) in patients with castration-resistant prostate cancer (CRPC). METHODS: We retrospectively compared the total cfDNA level and AR-amp in 42 individuals without prostate cancer, 57 patients with localized prostate cancer without androgen-deprivation therapy (ADT), 97 patients with castration-sensitive prostate cancer (CSPC) with ADT, and 97 patients with CRPC. The association of these cfDNA biomarkers on disease status and overall survival was evaluated using Kaplan-Meier analysis and multivariable Cox regression analysis. Finally, a simple risk model was developed including total cfDNA and AR-amp to predict poor prognosis. RESULTS: The median total cfDNA level and AR-amp in patients with CRPC was 387 pg/μL and 1.07 copies, respectively. The total cfDNA levels and AR-amp were significantly higher in the patients with CRPC than in individuals without prostate cancer, patients with localized prostate cancer without ADT, and patients with CSPC with ADT. Total cfDNA-high (> 600 pg/μL) and AR-amp-high (> 1.26 copies) were significantly associated with poor overall survival. Multivariable Cox regression analysis showed cfDNA-high and AR-amp-high were significantly associated with poor overall survival in patients with CRPC. We developed a risk model using cfDNA-high (score 1) and AR-amp-high (score 1). The risk score 1-2 was significantly associated with worse overall survival than score 0. CONCLUSION: Total cfDNA level and AR-amp are potential biomarkers for poor prognosis in patients with CRPC.
Authors: C Parker; E Castro; K Fizazi; A Heidenreich; P Ost; G Procopio; B Tombal; S Gillessen Journal: Ann Oncol Date: 2020-06-25 Impact factor: 32.976
Authors: Thomas Van den Broeck; Roderick C N van den Bergh; Erik Briers; Philip Cornford; Marcus Cumberbatch; Derya Tilki; Maria De Santis; Stefano Fanti; Nicola Fossati; Silke Gillessen; Jeremy P Grummet; Ann M Henry; Michael Lardas; Matthew Liew; Malcolm Mason; Lisa Moris; Ivo G Schoots; Theodorus van der Kwast; Henk van der Poel; Thomas Wiegel; Peter-Paul M Willemse; Olivier Rouvière; Thomas B Lam; Nicolas Mottet Journal: Eur Urol Focus Date: 2019-06-24
Authors: Himisha Beltran; Alessandro Romanel; Vincenza Conteduca; Nicola Casiraghi; Michael Sigouros; Gian Marco Franceschini; Francesco Orlando; Tarcisio Fedrizzi; Sheng-Yu Ku; Emma Dann; Alicia Alonso; Juan Miguel Mosquera; Andrea Sboner; Jenny Xiang; Olivier Elemento; David M Nanus; Scott T Tagawa; Matteo Benelli; Francesca Demichelis Journal: J Clin Invest Date: 2020-04-01 Impact factor: 14.808
Authors: Atish D Choudhury; Lillian Werner; Edoardo Francini; Xiao X Wei; Gavin Ha; Samuel S Freeman; Justin Rhoades; Sarah C Reed; Gregory Gydush; Denisse Rotem; Christopher Lo; Mary-Ellen Taplin; Lauren C Harshman; Zhenwei Zhang; Edward P O'Connor; Daniel G Stover; Heather A Parsons; Gad Getz; Matthew Meyerson; J Christopher Love; William C Hahn; Viktor A Adalsteinsson Journal: JCI Insight Date: 2018-11-02
Authors: Irene Casanova-Salas; Alejandro Athie; Paul C Boutros; Marzia Del Re; David T Miyamoto; Kenneth J Pienta; Edwin M Posadas; Adam G Sowalsky; Arnulf Stenzl; Alexander W Wyatt; Joaquin Mateo Journal: Eur Urol Date: 2021-01-07 Impact factor: 24.267